Lupin is expecting revenues of over Rs 780 crore (up to $150 million) from its oral contraceptive (OC) segment in the US market by 2013-14, a segment in which it had forayed recently. In September this year, the drug firm entered into OC segment in US after the US health regulator approved its generic norethindrone tablets in the strength of 0.35 mg.
The company has received two more approvals from the US Food and Drug Administration (USFDA) in the OC segment, since its foray taking the total approvals in the US market to three. Apart from generic norethindrone tablets, the company has received approvals from the USFDA to market generic versions of LoSeasonique tablets and Femcon Fe respectively.
Till date, the company's OC segment pipeline consists of 30 filings out of which it has already received approval for three generic drugs. The US market for oral contraceptives is pegged to be around $4.5 billion, according to industry estimates.
Further, according to IMS Health data, Lupin remains the fifth largest generic player in the US in terms of prescriptions and is currently the market leader in 14 out of 30 generic products in the US.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |